Please login to the form below

Not currently logged in
Email:
Password:

EMA Road Map consultation

The European Medicines Agency (EMA) has launched a public consultation on its Road Map to 2015, outlining its priorities for the next five years

The European Medicines Agency (EMA) has launched a public consultation on its Road Map to 2015, which outlines its priorities for the next five years and continues its previous five-year Road Map initiative.

European and international partners, stakeholders, including patients' and doctors' organisations as well as the pharmaceutical industry, and the public are invited to make their views known on the document, entitled The European Medicines Agency Road Map to 2015: The Agency's contribution to Science, Medicines, Health.

Building on the achievements of the previous Road Map initiative, covering 2005 to 2010, the focus of the new Road Map is on continuous high-quality delivery of the Agency's core business in an increasingly complex regulatory and scientific environment.

  • In addition, the document proposes three priority areas for future actions to strengthen the Agency's role in protecting and promoting human and animal health in the European Union. These include: Addressing public health needs by: stimulating research and medicines development in areas of unmet medical needs or for neglected and rare diseases; facilitating new and innovative approaches to the development of medicines; implementing effective preparedness plans to deal with public health threats  
  • Facilitating access to medicines by: addressing the high attrition rate during the development process of medicines; improving the Agency's model for the assessment of benefits and risks of medicines; improving the quality and scientific and regulatory consistency of the medicines review process
  • Optimising the safe use of medicines by: strengthening the evidence base on the benefits and risks of a medicine following its authorisation; applying novel pharmacovigilance methods and risk minimisation tools; by taking patient experience into account or improved decision making; becoming a reference point on information about medicines evaluated by the Agency.

Comments should be sent using the Agency's comments form by April 30, 2010 to: roadmap@ema.europa.eu

Final adoption is expected to take place in December 2010.


 

3rd February 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics